1 active not recruiting, 1 completed, 1 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Medullary Thyroid Cancer: new trials by email Literature Review of Medullary Thyroid Cancer trials Research Report on Medullary Thyroid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Withdrawn | Hoffmann-La Roche | 2023-11-30 | 2024-01-05 | |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 291 | 2020-02-11 | 2026-03-19 |
| Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Patient outreach, Vandetanib - Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer | Phase 3 | Completed | Sanofi | 205 | 2011-02-25 | 2026-04-17 |
Carcinoma, Medullary (3) · Neoplasm Metastasis (1)
Adenocarcinoma (3) · Carcinoma (3) · Carcinoma, Neuroendocrine (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Ductal, Lobular, and Medullary (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
vandetanib (3) · cabozantinib (2) · pralsetinib (1) · selpercatinib (1)
Hoffmann-La Roche (1) · Loxo Oncology, Inc. (1) · Sanofi (1)
Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · Czechia (2) · Germany (2) · Greece (2) · India (2) · Israel (2) · Italy (2) · Poland (2) · Russia (2) · South Korea (2) · Spain (2)
PMID 34292174, PMID 35969032, PMID 37870969, PMID 39694978, PMID 40617171
2019 (1)